Contact
searchSearch
HMP Global
Login
CD20-CD3
Biological Pathway Review
CD20-CD3 Expression in Cancer

Bladder Cancer

In muscle-invasive tumor cases of bladder cancer, the presence of CD3 tumor-infiltrating lymphocytes is associated with a good prognosis.5

Breast Cancer

Higher CD3 intratumoural and stromal counts showed independent and direct association with good prognosis in patients with breast cancer.6

Chronic Lymphocytic Leukemia

In patients with chronic lymphocytic leukemia, high levels of CD20 expression is associated with a good prognosis.7

Diffuse Large B-Cell Lymphoma

Reduced CD20 expression in diffuse large B-cell lymphoma is associated with inferior overall survival.8

Follicular Lymphoma

A loss in CD20 expression after chemoimmunotherapy is reported in patients with follicular lymphoma.9

Gastric Cancer

Higher number of CD3 T cells in tumor tissue are correlated with lower frequencies of lymph node metastasis, disease recurrence, or longer patient survival in gastric cancers.10

Mantle Cell Lymphoma

Mantle cell lymphoma typically expresses CD20.11

Non-Small-Cell Lung Cancer

The presence of CD3 T lymphocytes is useful in predicting the prognosis of radically resected patients with non-small cell lung cancer.12

Ovarian Cancer

In patients with ovarian cancer, the presence of CD3 tumor-infiltrating T cells is associated with improved clinical outcomes.13

CD20-CD3

CD20-CD3

CD20 is a non-glycosylated transmembrane protein that is expressed on the surface of normal and malignant B lymphocytes.1 It is a general B-cell marker involved in the development and differentiation of B cells.2 The biologic function of CD20 is unclear, but it is variably expressed in many B-cell malignancies and considered an ideal therapeutic target.1

CD3 is a T-cell activator protein that is made up of 4 molecules (γ, δ, ϵ, and ζ). The CD3 molecules assemble together with T-cell receptor (TCR) heterodimers to form a complex that signals T-cells to activate.3 TCR/CD3 signaling initiates T-cell responses to tumor cells.4

Understanding the Role of CD20-CD3

Multimedia

Ryan Lynch, MD, Fred Hutch Cancer Center
Videos
Evaluating Early Complete Responses of Mosunetuzumab Monotherapy for Patients With Previously Untreated Follicular Lymphoma and MZL
12/21/2023
Ryan Lynch, MD
At the 65th ASH Annual Meeting, Ryan C Lynch, MD, presented data on the high complete response rates of mosunetuzumab in previously untreated patients with follicular lymphoma and marginal zone lymphoma and only low-grade cytokine release...
At the 65th ASH Annual Meeting, Ryan C Lynch, MD, presented data on the high complete response rates of mosunetuzumab in previously untreated patients with follicular lymphoma and marginal zone lymphoma and only low-grade cytokine release...
At the 65th ASH Annual Meeting,...
12/21/2023
Oncology
Matthew Matasar, MD
Videos
Updates on the Safety, Efficacy of Mosunetuzumab Therapy for Patients With R/R Follicular Lymphoma
09/22/2023
Matthew Matasar, MD
Matthew Matasar, MD, shares updated results from a pivotal phase 2 study on the efficacy and safety of mosunetuzumab monotherapy among patients with relapsed/refractory follicular lymphoma.
Matthew Matasar, MD, shares updated results from a pivotal phase 2 study on the efficacy and safety of mosunetuzumab monotherapy among patients with relapsed/refractory follicular lymphoma.
Matthew Matasar, MD, shares...
09/22/2023
Oncology
Matthew Matasar, MD, Rutgers Cancer Institute of New Jersey
Videos
Mosunetuzumab Demonstrates Favorable Efficacy and Tolerability in Relapsed/Refractory Follicular Lymphoma
11/16/2022
Matthew Matasar, MD, discusses a phase 2 study assessing the safety and efficacy of fixed-duration mosunetuzumab, a CD20-CD3 T-cell-engaging bispecific monoclonal antibody, for relapsed/refractory follicular lymphoma.
Matthew Matasar, MD, discusses a phase 2 study assessing the safety and efficacy of fixed-duration mosunetuzumab, a CD20-CD3 T-cell-engaging bispecific monoclonal antibody, for relapsed/refractory follicular lymphoma.
Matthew Matasar, MD, discusses a...
11/16/2022
Oncology
Interview
Case Study Shows Success of Ibrutinib for CLL/SLL After Allo-HSCT
08/11/2021
Masatoshi Sakurai, MD, PhD, discusses the successful use of ibrutinib in a patient with CLL/SLL who had CNS relapse approximately 10 years after allo-HSCT.
Masatoshi Sakurai, MD, PhD, discusses the successful use of ibrutinib in a patient with CLL/SLL who had CNS relapse approximately 10 years after allo-HSCT.
Masatoshi Sakurai, MD, PhD,...
08/11/2021
Oncology
Dr Jason Westin
Videos
Dr Westin on Brexucabtagene Autoleucel as a “Transformative” CAR-T Therapy for R/R MCL
08/06/2021
Jason Westin, MD, FACP, discusses the ZUMA-2 trial on brexucabtagene autleucel, an anti-CD19 CAR -T therapy, for pretreated patients with R/R MCL.
Jason Westin, MD, FACP, discusses the ZUMA-2 trial on brexucabtagene autleucel, an anti-CD19 CAR -T therapy, for pretreated patients with R/R MCL.
Jason Westin, MD, FACP, ...
08/06/2021
Oncology
Paolo Ghia, MD, PhD
Videos
Combo Therapy Demonstrates Durable Responses in Patients With CLL
06/07/2021
Paolo Ghia, MD, PhD, discusses the CAPTIVATE study of ibrutinib plus venetoclax in patients with CLL. These data are being presented at the 2021 ASCO Annual Meeting.
Paolo Ghia, MD, PhD, discusses the CAPTIVATE study of ibrutinib plus venetoclax in patients with CLL. These data are being presented at the 2021 ASCO Annual Meeting.
Paolo Ghia, MD, PhD, discusses...
06/07/2021
Oncology
Paul Barr, MD
Videos
Ibrutinib Therapy Demonstrates Sustained PFS, OS in Patients With CLL/SLL
06/04/2021
Paul Barr, MD, shares findings from the RESONATE-2 study of ibrutinib in patients with CLL/SLL. These data are being presented at the 2021 ASCO Annual Meeting.
Paul Barr, MD, shares findings from the RESONATE-2 study of ibrutinib in patients with CLL/SLL. These data are being presented at the 2021 ASCO Annual Meeting.
Paul Barr, MD, shares findings...
06/04/2021
Oncology
Jennifer Brudno, MD
Videos
Jennifer Brudno, MD, Discusses Anti-CD19 CAR-T Therapy for B-Cell Lymphoma
05/20/2021
Jennifer Brudno, MD, discusses the safety and feasibility of anti-CD19 CAR-T therapy for patients with B-cell lymphoma.
Jennifer Brudno, MD, discusses the safety and feasibility of anti-CD19 CAR-T therapy for patients with B-cell lymphoma.
Jennifer Brudno, MD, discusses...
05/20/2021
Oncology
Videos
Kerry Rogers, MD, Discusses Triplet Combo Therapy for CLL
05/13/2021
Dr Rogers discusses her study on the combination of obinutuzumab, ibrutinib, and venetoclax for chronic lymphocytic leukemia.
Dr Rogers discusses her study on the combination of obinutuzumab, ibrutinib, and venetoclax for chronic lymphocytic leukemia.
Dr Rogers discusses her study on...
05/13/2021
Oncology
Podcasts
Nirav Shah, MD, Discusses Dual-Targeted CAR-T Therapy for NHL, CLL
05/07/2021
Dr Shah discusses his research on the use of a bi-specific anti-CD20/CD19 CAR-T therapy for patients with B-cell NHL or CLL.
Dr Shah discusses his research on the use of a bi-specific anti-CD20/CD19 CAR-T therapy for patients with B-cell NHL or CLL.
Dr Shah discusses his research...
05/07/2021
Oncology
Guilherme Rabinowits, MD
Videos
FID-007 Plus Cetuximab Demonstrates Encouraging Activity in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
06/05/2026
Guilherme Rabinowits, MD, discusses results from a phase 2 trial which demonstrated that FID-007 plus cetuximab showed promising activity and manageable safety in patients with recurrent or metastatic head and neck squamous cell carcinoma who...
Guilherme Rabinowits, MD, discusses results from a phase 2 trial which demonstrated that FID-007 plus cetuximab showed promising activity and manageable safety in patients with recurrent or metastatic head and neck squamous cell carcinoma who...
Guilherme Rabinowits, MD,...
06/05/2026
Oncology
Anastasios Maniakas, MD, PhD
Videos
ASP-1929 Photoimmunotherapy Demonstrates Clinical Benefit in Recurrent Head and Neck Squamous Cell Carcinoma
06/05/2026
Anastasios Maniakas, MD, PhD, discusses results from a phase 3 study which found that ASP-1929 photoimmunotherapy improved response and quality-of-life outcomes in recurrent head and neck squamous cell carcinoma.
Anastasios Maniakas, MD, PhD, discusses results from a phase 3 study which found that ASP-1929 photoimmunotherapy improved response and quality-of-life outcomes in recurrent head and neck squamous cell carcinoma.
Anastasios Maniakas, MD, PhD,...
06/05/2026
Oncology
Barbara Burtness, MD, FASCO
Videos
Amivantamab Demonstrates Durable Responses in HPV-Unrelated Head and Neck Squamous Cell Carcinoma
06/05/2026
Barbara Burtness, MD, FASCO, discusses phase 2 OrigAMI-4 results showing that subcutaneous amivantamab achieved a 47% response rate in HPV-unrelated recurrent/metastatic head and neck squamous cell carcinoma after progression on...
Barbara Burtness, MD, FASCO, discusses phase 2 OrigAMI-4 results showing that subcutaneous amivantamab achieved a 47% response rate in HPV-unrelated recurrent/metastatic head and neck squamous cell carcinoma after progression on...
Barbara Burtness, MD, FASCO,...
06/05/2026
Oncology
Elias Jabbour, MD
Podcasts
Olverembatinib Plus Blinatumomab Produces Deep Responses in Ph+ Acute Lymphoblastic Leukemia
06/05/2026
Elias Jabbour, MD
Elias Jabbour, MD, discusses results from a phase 1 study showing that olverembatinib plus blinatumomab induced high response rates and deep MRD-negative remissions in heavily pretreated patients with Philadelphia chromosome–positive acute...
Elias Jabbour, MD, discusses results from a phase 1 study showing that olverembatinib plus blinatumomab induced high response rates and deep MRD-negative remissions in heavily pretreated patients with Philadelphia chromosome–positive acute...
Elias Jabbour, MD, discusses...
06/05/2026
Oncology
Scott Kopetz, MD, PhD
Videos
Encorafenib and Cetuximab Plus FOLFIRI Improves Outcomes in BRAF V600E-Mutant Metastatic Colorectal Cancer
06/04/2026
Scott Kopetz, MD, PhD
Scott Kopetz, MD, PhD, FASCO, discusses phase 3 BREAKWATER Cohort 3 results showing that first-line encorafenib plus cetuximab and FOLFIRI improved response rates, progression-free survival, and overall survival vs standard therapy in BRAF...
Scott Kopetz, MD, PhD, FASCO, discusses phase 3 BREAKWATER Cohort 3 results showing that first-line encorafenib plus cetuximab and FOLFIRI improved response rates, progression-free survival, and overall survival vs standard therapy in BRAF...
Scott Kopetz, MD, PhD, FASCO,...
06/04/2026
Oncology
Daniel D'Angelo, MD
Videos
Novel Immunotherapy Combination Improves MRD-Negative Rates in B-Cell Acute Lymphoblastic Leukemia
06/03/2026
Daniel DeAngelo, MD, PhD
Daniel DeAngelo, MD, discusses data showing that the addition of inotuzumab ozogamicin to modified hyper-CVAD plus blinatumomab produced high remission and MRD-negative response rates with low relapse rates in patients with B-cell acute...
Daniel DeAngelo, MD, discusses data showing that the addition of inotuzumab ozogamicin to modified hyper-CVAD plus blinatumomab produced high remission and MRD-negative response rates with low relapse rates in patients with B-cell acute...
Daniel DeAngelo, MD, discusses...
06/03/2026
Oncology
John Mascarenhas, MD
Videos
Selinexor Plus Ruxolitinib Demonstrates Clinical Benefit in JAK Inhibitor–Naïve Myelofibrosis
06/03/2026
John Mascarenhas, MD
John Mascarenhas, MD, discusses results from the phase 3 SENTRY trial showing that the addition of selinexor to ruxolitinib improved spleen responses, enhanced molecular response rates, and demonstrated an early overall survival signal in JAK...
John Mascarenhas, MD, discusses results from the phase 3 SENTRY trial showing that the addition of selinexor to ruxolitinib improved spleen responses, enhanced molecular response rates, and demonstrated an early overall survival signal in JAK...
John Mascarenhas, MD, discusses...
06/03/2026
Oncology
Ronald Chen, MD, MPH
Videos
Pembrolizumab Improves DFS Without Compromising HRQOL in High-Risk Muscle-Invasive Urothelial Carcinoma
06/01/2026
Ronald Chen, MD, MPH, FASCO
Ronald Chen, MD, reviews results from the AMBASSADOR trial showing that adjuvant pembrolizumab improved disease-free survival in patients with high-risk muscle-invasive urothelial carcinoma without negatively affecting health-related quality...
Ronald Chen, MD, reviews results from the AMBASSADOR trial showing that adjuvant pembrolizumab improved disease-free survival in patients with high-risk muscle-invasive urothelial carcinoma without negatively affecting health-related quality...
Ronald Chen, MD, reviews results...
06/01/2026
Oncology
Glenn Hanna, MD
Videos
Emi-Le Demonstrates Promising Activity in Aggressive Adenoid Cystic Carcinoma
06/01/2026
Glenn Hanna, MD
Glenn Hanna, MD, discusses promising phase 1 results for emiltatug ledadotin (Emi-Le; XMT-1660), a novel B7-H4-directed antibody-drug conjugate that demonstrated encouraging efficacy and a favorable safety profile in patients with aggressive...
Glenn Hanna, MD, discusses promising phase 1 results for emiltatug ledadotin (Emi-Le; XMT-1660), a novel B7-H4-directed antibody-drug conjugate that demonstrated encouraging efficacy and a favorable safety profile in patients with aggressive...
Glenn Hanna, MD, discusses...
06/01/2026
Oncology
Brian Wolpin, MD
Videos
Daraxonrasib Improves Survival Outcomes in Previously Treated Metastatic Pancreatic Cancer
05/31/2026
Brian Wolpin, MD, MPH, presents results from the phase 3 RASolute 302 trial showing daraxonrasib significantly improved overall survival, progression-free survival, and response rates vs standard chemotherapy in previously treated metastatic...
Brian Wolpin, MD, MPH, presents results from the phase 3 RASolute 302 trial showing daraxonrasib significantly improved overall survival, progression-free survival, and response rates vs standard chemotherapy in previously treated metastatic...
Brian Wolpin, MD, MPH, presents...
05/31/2026
Oncology

Latest News

News
Pharmacology Model Predicts Treatment Benefits of Mosunetuzumab Among Patients With Non-Hodgkin Lymphoma
03/23/2023
Jordan Kadish
According to the phase 1/2 GO29781 trial, a quantitative systems pharmacology model predicted increased exposure to mosunetuzumab led to tumor size reduction among patients with non-Hodgkin lymphoma.
According to the phase 1/2 GO29781 trial, a quantitative systems pharmacology model predicted increased exposure to mosunetuzumab led to tumor size reduction among patients with non-Hodgkin lymphoma.
According to the phase 1/2...
03/23/2023
Oncology
News
Epcoritamab Yields High Overall and Complete Response Rates for Patients With R/R CD20+ LBCL
03/15/2023
Jordan Kadish
According to a phase 1/2 study, CD3-CD20 bispecific t-cell engaging antibody epcoritamab resulted in high overall response and complete response rates profile among patients with R/R CD20+ large b-cell lymphoma.
According to a phase 1/2 study, CD3-CD20 bispecific t-cell engaging antibody epcoritamab resulted in high overall response and complete response rates profile among patients with R/R CD20+ large b-cell lymphoma.
According to a phase 1/2 study,...
03/15/2023
Oncology
News
Subcutaneous Epcoritamab Combined With R-Dhax/C Yielded High ORR and CMR Rates in Patients With R/R DLBCL
02/10/2023
Jordan Kadish
An updated phase 1/2 dose escalation study found that a combination of subcutaneous epcoritamab and R-Dhax/C luxeptinib for patients with R/R diffuse b-cell lymphoma resulted in high ORR and CMR rates.
An updated phase 1/2 dose escalation study found that a combination of subcutaneous epcoritamab and R-Dhax/C luxeptinib for patients with R/R diffuse b-cell lymphoma resulted in high ORR and CMR rates.
An updated phase 1/2 dose...
02/10/2023
Oncology
News
Odronextamab Demonstrates Promising Safety, Response in R/R Non-Hodgkin Lymphoma
11/17/2022
Gina Tomaine
CD20-CD3 bispecific antibody odronextamab showed a manageable safety profile and encouraging preliminary activity in heavily pretreated patients with B-cell non-Hodgkin lymphoma, according to a recent phase 1 study.
CD20-CD3 bispecific antibody odronextamab showed a manageable safety profile and encouraging preliminary activity in heavily pretreated patients with B-cell non-Hodgkin lymphoma, according to a recent phase 1 study.
CD20-CD3 bispecific antibody...
11/17/2022
Oncology
News
Mosunetuzumab Demonstrates Safety, Efficacy in Patients With Relapsed/Refractory Follicular Lymphoma
11/17/2022
Gina Tomaine
CD20-CD3 bispecific antibody mosunetuzumab demonstrated a favorable safety profile and induced high rates of complete remission in patients with relapsed/refractory follicular lymphoma, according to a phase 2 study.
CD20-CD3 bispecific antibody mosunetuzumab demonstrated a favorable safety profile and induced high rates of complete remission in patients with relapsed/refractory follicular lymphoma, according to a phase 2 study.
CD20-CD3 bispecific antibody...
11/17/2022
Oncology
News
CD20-CD3 Bispecific Antibody Shows High Efficacy in Relapsed/Refractory Follicular Lymphoma
03/08/2022
A pivotal expansion cohort of mosunetuzumab showed high potency for R/R FL with 3 out of 4 patients experiencing an ORR of 78.9%.
A pivotal expansion cohort of mosunetuzumab showed high potency for R/R FL with 3 out of 4 patients experiencing an ORR of 78.9%.
A pivotal expansion cohort of...
03/08/2022
Oncology
News
CRS Tool Predicts Risk Events in Patients With R/R NHL Receiving Glofitamab
02/07/2022
A management tool for grade ≥ 2 CRS events was developed to enable stratification in patients with R/R NHL who receive glofitamab, presented at ASH 2021.
A management tool for grade ≥ 2 CRS events was developed to enable stratification in patients with R/R NHL who receive glofitamab, presented at ASH 2021.
A management tool for grade ≥ 2...
02/07/2022
Oncology
News
IGM-2323 Shows Favorable Safety Profile With Advanced B-Cell Malignancies
02/01/2022
IGM-2323, an anti-CD20 x anti-CD3 IgM T-cell engager, achieves complete responses and a favorable safety profile in patients with advanced B-cell malignancies, presented at ASH 2021.
IGM-2323, an anti-CD20 x anti-CD3 IgM T-cell engager, achieves complete responses and a favorable safety profile in patients with advanced B-cell malignancies, presented at ASH 2021.
IGM-2323, an anti-CD20 x...
02/01/2022
Oncology
News
CT-P10 and Rituximab Yield Favorable Outcomes in Patients With FL
10/04/2021
Findings from a randomized phase 3 study showed the efficacy and safety of CT-P10 or rituximab in patients with untreated advanced FL.
Findings from a randomized phase 3 study showed the efficacy and safety of CT-P10 or rituximab in patients with untreated advanced FL.
Findings from a randomized phase...
10/04/2021
Oncology
Interview
Case Study Shows Success of Ibrutinib for CLL/SLL After Allo-HSCT
08/11/2021
Masatoshi Sakurai, MD, PhD, discusses the successful use of ibrutinib in a patient with CLL/SLL who had CNS relapse approximately 10 years after allo-HSCT.
Masatoshi Sakurai, MD, PhD, discusses the successful use of ibrutinib in a patient with CLL/SLL who had CNS relapse approximately 10 years after allo-HSCT.
Masatoshi Sakurai, MD, PhD,...
08/11/2021
Oncology
Guilherme Rabinowits, MD
Videos
FID-007 Plus Cetuximab Demonstrates Encouraging Activity in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
06/05/2026
Guilherme Rabinowits, MD, discusses results from a phase 2 trial which demonstrated that FID-007 plus cetuximab showed promising activity and manageable safety in patients with recurrent or metastatic head and neck squamous cell carcinoma who...
Guilherme Rabinowits, MD, discusses results from a phase 2 trial which demonstrated that FID-007 plus cetuximab showed promising activity and manageable safety in patients with recurrent or metastatic head and neck squamous cell carcinoma who...
Guilherme Rabinowits, MD,...
06/05/2026
Oncology
Anastasios Maniakas, MD, PhD
Videos
ASP-1929 Photoimmunotherapy Demonstrates Clinical Benefit in Recurrent Head and Neck Squamous Cell Carcinoma
06/05/2026
Anastasios Maniakas, MD, PhD, discusses results from a phase 3 study which found that ASP-1929 photoimmunotherapy improved response and quality-of-life outcomes in recurrent head and neck squamous cell carcinoma.
Anastasios Maniakas, MD, PhD, discusses results from a phase 3 study which found that ASP-1929 photoimmunotherapy improved response and quality-of-life outcomes in recurrent head and neck squamous cell carcinoma.
Anastasios Maniakas, MD, PhD,...
06/05/2026
Oncology
Barbara Burtness, MD, FASCO
Videos
Amivantamab Demonstrates Durable Responses in HPV-Unrelated Head and Neck Squamous Cell Carcinoma
06/05/2026
Barbara Burtness, MD, FASCO, discusses phase 2 OrigAMI-4 results showing that subcutaneous amivantamab achieved a 47% response rate in HPV-unrelated recurrent/metastatic head and neck squamous cell carcinoma after progression on...
Barbara Burtness, MD, FASCO, discusses phase 2 OrigAMI-4 results showing that subcutaneous amivantamab achieved a 47% response rate in HPV-unrelated recurrent/metastatic head and neck squamous cell carcinoma after progression on...
Barbara Burtness, MD, FASCO,...
06/05/2026
Oncology
News
Eganelisib Demonstrates Early Activity in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes
06/05/2026
Emily Estrada
Results from a phase 1 study demonstrated that eganelisib showed promising preliminary activity in heavily pretreated patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes.
Results from a phase 1 study demonstrated that eganelisib showed promising preliminary activity in heavily pretreated patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes.
Results from a phase 1 study...
06/05/2026
Oncology
News
Fedratinib Demonstrates Potential Clinical Promise in Patients With Proliferative MDS/MPNs and Chronic Neutrophilic Leukemia
06/05/2026
Emily Estrada
Results from a phase 2 study demonstrated that fedratinib showed promising clinical activity among patients with myelodysplastic and myeloproliferative neoplasms and chronic neutrophilic leukemia.
Results from a phase 2 study demonstrated that fedratinib showed promising clinical activity among patients with myelodysplastic and myeloproliferative neoplasms and chronic neutrophilic leukemia.
Results from a phase 2 study...
06/05/2026
Oncology
News
Fluoxetine Plus Chemoradiotherapy Shows Potential Activity in Newly Diagnosed High-Grade Glioma
06/05/2026
Emily Estrada
Results from a phase 2 study suggest that the addition of fluoxetine to standard chemoradiotherapy was feasible and had manageable toxicity among newly diagnosed patients with grade 4 glioma.
Results from a phase 2 study suggest that the addition of fluoxetine to standard chemoradiotherapy was feasible and had manageable toxicity among newly diagnosed patients with grade 4 glioma.
Results from a phase 2 study...
06/05/2026
Oncology
News
ACT001 Plus Radiotherapy Shows Strong Clinical Promise in Newly Diagnosed Pediatric Diffuse Intrinsic Pontine Glioma
06/05/2026
Emily Estrada
Results from a phase 2 trial demonstrated that ACT001 combined with radiotherapy showed encouraging clinical promise in newly diagnosed pediatric patients with diffuse intrinsic pontine glioma.
Results from a phase 2 trial demonstrated that ACT001 combined with radiotherapy showed encouraging clinical promise in newly diagnosed pediatric patients with diffuse intrinsic pontine glioma.
Results from a phase 2 trial...
06/05/2026
Oncology
Scott Kopetz, MD, PhD
Videos
Encorafenib and Cetuximab Plus FOLFIRI Improves Outcomes in BRAF V600E-Mutant Metastatic Colorectal Cancer
06/04/2026
Scott Kopetz, MD, PhD
Scott Kopetz, MD, PhD, FASCO, discusses phase 3 BREAKWATER Cohort 3 results showing that first-line encorafenib plus cetuximab and FOLFIRI improved response rates, progression-free survival, and overall survival vs standard therapy in BRAF...
Scott Kopetz, MD, PhD, FASCO, discusses phase 3 BREAKWATER Cohort 3 results showing that first-line encorafenib plus cetuximab and FOLFIRI improved response rates, progression-free survival, and overall survival vs standard therapy in BRAF...
Scott Kopetz, MD, PhD, FASCO,...
06/04/2026
Oncology
News
Enfortumab Vedotin Plus Pembrolizumab Maintains Long-Term Survival Benefit in Advanced Urothelial Carcinoma
06/01/2026
Emily Estrada
Results from the EV-302/KEYNOTE-A39 trial demonstrated that enfortumab vedotin plus pembrolizumab maintained a durable survival benefit in previously untreated patients with locally advanced or metastatic urothelial carcinoma.
Results from the EV-302/KEYNOTE-A39 trial demonstrated that enfortumab vedotin plus pembrolizumab maintained a durable survival benefit in previously untreated patients with locally advanced or metastatic urothelial carcinoma.
Results from the...
06/01/2026
Oncology
Ronald Chen, MD, MPH
Videos
Pembrolizumab Improves DFS Without Compromising HRQOL in High-Risk Muscle-Invasive Urothelial Carcinoma
06/01/2026
Ronald Chen, MD, MPH, FASCO
Ronald Chen, MD, reviews results from the AMBASSADOR trial showing that adjuvant pembrolizumab improved disease-free survival in patients with high-risk muscle-invasive urothelial carcinoma without negatively affecting health-related quality...
Ronald Chen, MD, reviews results from the AMBASSADOR trial showing that adjuvant pembrolizumab improved disease-free survival in patients with high-risk muscle-invasive urothelial carcinoma without negatively affecting health-related quality...
Ronald Chen, MD, reviews results...
06/01/2026
Oncology

Interactive Features

Quiz
Treating DLBCL With Odronextamab Monotherapy
12/18/2023
Updated analysis of outcomes in the ELM-1 trial demonstrated that CD20-CD3 bispecific antibody odronextamab monotherapy demonstrated _____ among heavily pretreated patients with diffuse large B-cell lymphoma (DLBCL) who had progressed after...
Updated analysis of outcomes in the ELM-1 trial demonstrated that CD20-CD3 bispecific antibody odronextamab monotherapy demonstrated _____ among heavily pretreated patients with diffuse large B-cell lymphoma (DLBCL) who had progressed after...
Updated analysis of outcomes in...
12/18/2023
Oncology
Quiz
Mosunetuzumab Monotherapy for FL and MZL With No G2+ CRS or ICANS
12/18/2023
True or False: Fixed-duration mosunetuzumab monotherapy demonstrated a high complete response rate and well-tolerated safety among patients with follicular lymphoma and MZL with no G2+ cytokine release syndrome and no ICANS of any grade.
True or False: Fixed-duration mosunetuzumab monotherapy demonstrated a high complete response rate and well-tolerated safety among patients with follicular lymphoma and MZL with no G2+ cytokine release syndrome and no ICANS of any grade.
True or False: Fixed-duration...
12/18/2023
Oncology
Quiz
Quiz: CD20-CD3 for Malignant B-Cells
03/20/2023
CD20 is a ________ protein that is expressed on the surface of normal and malignant B lymphocytes. CD3 is a ________ protein that is made up of 4 molecules (γ, δ, ϵ, and ζ).
CD20 is a ________ protein that is expressed on the surface of normal and malignant B lymphocytes. CD3 is a ________ protein that is made up of 4 molecules (γ, δ, ϵ, and ζ).
CD20 is a ________ protein that...
03/20/2023
Oncology
Quiz
Quiz: Complete Response Rate of Mosunetuzumab in Patients With Relapsed/Refractory Follicular Lymphoma
12/05/2022
According to a phase 2 study, what was the complete response rate of mosunetuzumab in patients with relapsed/refractory follicular lymphoma who had previously been treated with ≥2 therapies?
According to a phase 2 study, what was the complete response rate of mosunetuzumab in patients with relapsed/refractory follicular lymphoma who had previously been treated with ≥2 therapies?
According to a phase 2 study,...
12/05/2022
Oncology
Quiz
Quiz: Odronextamab Monotherapy in Heavily Pretreated Patients With B-cell Non-Hodgkin Lymphoma
12/01/2022
True or False: Odronextamab monotherapy demonstrated a manageable safety profile and encouraging preliminary activity in heavily pretreated patients with B-cell non-Hodgkin lymphoma, according to a recent study.
True or False: Odronextamab monotherapy demonstrated a manageable safety profile and encouraging preliminary activity in heavily pretreated patients with B-cell non-Hodgkin lymphoma, according to a recent study.
True or False: Odronextamab...
12/01/2022
Oncology
Quiz
Quiz: Does This CD20xCD3 Bispecific Antibody Show High Potency?
04/11/2022
True or false: Mosunetuzumab showed high potency in patients with R/R FL.
True or false: Mosunetuzumab showed high potency in patients with R/R FL.
True or false: Mosunetuzumab...
04/11/2022
Oncology
Test Your Knowledge
Quiz: Can IGM-2323 Mitigate CRS-Related Toxicities in CD20+ NHL?
02/02/2022
True or false: IGM-2323 can mitigate CRS-related toxicities in R/R CD20+ B-cell NHL.
True or false: IGM-2323 can mitigate CRS-related toxicities in R/R CD20+ B-cell NHL.
True or false: IGM-2323 can...
02/02/2022
Oncology
Test Your Knowledge
Quiz: Is Rituximab an Effective Anti-CD20 Monoclonal Antibody in Advanced FL?
10/26/2021
True or false: In a phase 3 trial, rituximab failed to effectively treat patients with advanced FL as an anti-CD20 monoclonal antibody.
True or false: In a phase 3 trial, rituximab failed to effectively treat patients with advanced FL as an anti-CD20 monoclonal antibody.
True or false: In a phase 3...
10/26/2021
Oncology
Test Your Knowledge
Quiz: Can Thoracic Spine Masses Express CD20 Cells in CLL/SLL?
10/26/2021
True or false: Thoracic spine masses treated for CLL/SLL can proliferate mononuclear CD20 cells.
True or false: Thoracic spine masses treated for CLL/SLL can proliferate mononuclear CD20 cells.
True or false: Thoracic spine...
10/26/2021
Oncology
White Blood Cell Count Control in Polycythemia Vera (PV) Management: A Quiz Journey
PV Management Question 4
05/21/2026
Lucia Masarova, MD
Test your understanding of the relationship between leukocytosis, symptom burden, and disease activity in polycythemia vera.
Test your understanding of the relationship between leukocytosis, symptom burden, and disease activity in polycythemia vera.
Test your understanding of the...
05/21/2026
Oncology
White Blood Cell Count Control in Polycythemia Vera (PV) Management: A Quiz Journey
PV Management Question 3
05/21/2026
Lucia Masarova, MD
Learn how persistent leukocytosis may inform assessment of disease control and management decisions in polycythemia vera.
Learn how persistent leukocytosis may inform assessment of disease control and management decisions in polycythemia vera.
Learn how persistent...
05/21/2026
Oncology
White Blood Cell Count Control in Polycythemia Vera (PV) Management: A Quiz Journey
PV Management Question 2
05/21/2026
Lucia Masarova, MD
Review evidence evaluating the association between elevated white blood cell count and thrombotic risk in polycythemia vera.
Review evidence evaluating the association between elevated white blood cell count and thrombotic risk in polycythemia vera.
Review evidence evaluating the...
05/21/2026
Oncology
White Blood Cell Count Control in Polycythemia Vera (PV) Management: A Quiz Journey
PV Management Question 1
05/21/2026
Lucia Masarova, MD
Test your knowledge of the clinical relevance of white blood cell count control in polycythemia vera management.
Test your knowledge of the clinical relevance of white blood cell count control in polycythemia vera management.
Test your knowledge of the...
05/21/2026
Oncology
Current First-Line Treatments and Low-Risk Treatment Guidelines in Polycythemia Vera (PV): A Quiz Journey
PV Guidelines Question 5
05/21/2026
Michael R. Grunwald, MD
Learn more about the safety profile of interferon therapy in low-risk polycythemia vera.
Learn more about the safety profile of interferon therapy in low-risk polycythemia vera.
Learn more about the safety...
05/21/2026
Oncology
Current First-Line Treatments and Low-Risk Treatment Guidelines in Polycythemia Vera (PV): A Quiz Journey
PV Guidelines Question 4
05/21/2026
Michael R. Grunwald, MD
Review clinical features that may support consideration of cytoreductive therapy in patients with low-risk polycythemia vera.
Review clinical features that may support consideration of cytoreductive therapy in patients with low-risk polycythemia vera.
Review clinical features that...
05/21/2026
Oncology
Current First-Line Treatments and Low-Risk Treatment Guidelines in Polycythemia Vera (PV): A Quiz Journey
PV Guidelines Question 3
05/21/2026
Michael R. Grunwald, MD
Test your understanding of first-line cytoreductive therapy options for patients with high-risk polycythemia vera.
Test your understanding of first-line cytoreductive therapy options for patients with high-risk polycythemia vera.
Test your understanding of...
05/21/2026
Oncology
Current First-Line Treatments and Low-Risk Treatment Guidelines in Polycythemia Vera (PV): A Quiz Journey
PV Guidelines Question 2
05/20/2026
Learn when cytoreductive therapy should be considered for patients with low-risk polycythemia vera despite treatment with phlebotomy and aspirin.
Learn when cytoreductive therapy should be considered for patients with low-risk polycythemia vera despite treatment with phlebotomy and aspirin.
Learn when cytoreductive therapy...
05/20/2026
Oncology
Current First-Line Treatments and Low-Risk Treatment Guidelines in Polycythemia Vera (PV): A Quiz Journey
PV Guidelines Question 1
05/20/2026
Michael R. Grunwald, MD
Test your knowledge of current first-line treatment strategies in polycythemia vera.
Test your knowledge of current first-line treatment strategies in polycythemia vera.
Test your knowledge of current...
05/20/2026
Oncology
Quiz
Molecular Predictors of Survival With Ruxolitinib Plus Venetoclax in R/R Acute Myeloid Leukemia
05/01/2026
Which genomic feature predicts poor survival with ruxolitinib plus venetoclax in patients with R/R acute myeloid leukemia?
Which genomic feature predicts poor survival with ruxolitinib plus venetoclax in patients with R/R acute myeloid leukemia?
Which genomic feature predicts...
05/01/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use